Cell Free Circulating DNA Prague Spring Symposium 2016 The Centre of Medical Genetics and Reproductive Medicine (GENNET) and BGI are pleased to invite you to the Cell Free Circulating DNA Prague Spring Symposium, 2016. The symposium will consist of two half-day meetings on the afternoon of Friday, April 29 and the morning of Saturday, April 30. Friday’s session will be followed…
On April 1st, 2015 – Researchers from the Baylor College of Medicine, the Chinese University of Hong Kong and the University of Hong Kong have published a study titled Accurate Description of DNA-Based Noninvasive Prenatal Screening in The New England Journal of Medicine. The study found that BGI’s NIFTY® test performed better than all other NIPT tests examined. In the study, researchers evaluated the performance of…
January 28th – BGI has published a study tracking the clinical performance of its whole genome sequencing-based non-invasive prenatal test (the NIFTY® test) in nearly 147,000 pregnancies, the largest such study to date. The results showed high sensitivity and specificity and no significant difference between high-risk and low-risk pregnant women.
The goals of the study were to develop a noninvasive pre- natal test for autosomal recessive monogenic conditions and to prove its overall feasibility and potential for clinical integration.
December 3rd, 2014 – BGI Europe and NIM Genetics, one of Spain’s leading genetic diagnostics companies, are pleased to announce the signing of an exclusive technology transfer agreement whereby BGI Europe will transfer its science and technology in the field of non-invasive prenatal testing.
July 2, 2014 – BGI Diagnostics’ NIFTY™ test becomes First NIPT based on Next Generation Sequencing Technology to be Approved by the China Food and Drug Administration (CFDA).
English
Viet Nam